» Articles » PMID: 32175272

Is Highly Expressed and Associated With Poor Survival in Acute Myeloid Leukemia

Overview
Journal Front Oncol
Specialty Oncology
Date 2020 Mar 17
PMID 32175272
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

The F-box and WD repeat domain-containing (FBXW) proteins play an important role in ubiquitin proteasome by inducing protein degradation. Ten FBXW proteins have been identified in humans. The functions of FBXW proteins, like FBXW7, have been well-established in many human cancers. However, little is known about their transcriptional expression profiles and relationship with prognosis in acute myeloid leukemia (AML). Here we investigated the roles of FBXW proteins in AML by analyzing their mRNA expression profiles and association with clinical features using data from EMBL-EBI, the Cancer Cell Line Encyclopedia, Gene Expression Profiling Interactive Analysis, and cBioPortal databases. Our results showed that the mRNA level of FBXW proteins were highly detected by microarray in 14 AML cell lines, although there were no obvious differences. The expression of was significantly higher in AML patients compared with that in normal controls ( < 0.01). Patients whose age was ≥60 years old had a higher expression when compared with those who were <60 years old ( < 0.05). Cytogenetic favorable-risk group patients had a much lower expression than the intermediate- and poor-risk group patients ( < 0.0001). Moreover, patients with high expression exhibited significantly shorter event-free survival (EFS) and overall survival (OS) than those with low expression (median EFS: 5.3 vs. 10.0 months, = 0.025; median OS: 8.1 vs. 19.0 months, = 0.015). A multivariate analysis indicated that high expression was an independent risk factor for poor EFS in AML patients who received intensive chemotherapy followed by allo-SCT. In summary, our data suggested that is aberrantly expressed in AML and high expression might be a poor prognostic biomarker; future functional and mechanistic studies will further illuminate the roles of in AML.

Citing Articles

Elucidating the role of FBXW4 in osteoporosis: integrating bioinformatics and machine learning for advanced insight.

Li J, Li J, Zheng M, Liu J, Zhao X BMC Pharmacol Toxicol. 2025; 26(1):20.

PMID: 39881357 PMC: 11781060. DOI: 10.1186/s40360-025-00844-z.


Pivotal Role of FBXW4 in Glioma Progression and Prognosis.

Chen K, Pu L, Hui Y Genet Res (Camb). 2024; 2024:3005195.

PMID: 39377096 PMC: 11458277. DOI: 10.1155/2024/3005195.


A Comprehensive Analysis Revealing FBXW9 as a Potential Prognostic and Immunological Biomarker in Breast Cancer.

Yu S, Liang Z, Fan Z, Cao B, Wang N, Wu R Int J Mol Sci. 2023; 24(6).

PMID: 36982338 PMC: 10049633. DOI: 10.3390/ijms24065262.


SCF-FBXL8 contributes to liver metastasis and stem-cell-like features in colorectal cancer cells by mediating ubiquitination and degradation of TP53.

Yao J, Wang X, Yang J, Yang Z, Zhang Z Clin Transl Med. 2023; 13(3):e1208.

PMID: 36855778 PMC: 9975457. DOI: 10.1002/ctm2.1208.


FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia.

Zhu X, Wei Y, Yang Q, Liu H, Zhi Z, Zhu D J Hematol Oncol. 2023; 16(1):9.

PMID: 36774506 PMC: 9922468. DOI: 10.1186/s13045-023-01400-0.


References
1.
Yeh C, Bellon M, Pancewicz-Wojtkiewicz J, Nicot C . Oncogenic mutations in the FBXW7 gene of adult T-cell leukemia patients. Proc Natl Acad Sci U S A. 2016; 113(24):6731-6. PMC: 4914202. DOI: 10.1073/pnas.1601537113. View

2.
Bullinger L, Dohner K, Dohner H . Genomics of Acute Myeloid Leukemia Diagnosis and Pathways. J Clin Oncol. 2017; 35(9):934-946. DOI: 10.1200/JCO.2016.71.2208. View

3.
Levis M, Brown P, Smith B, Stine A, Pham R, Stone R . Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood. 2006; 108(10):3477-83. PMC: 1895426. DOI: 10.1182/blood-2006-04-015743. View

4.
Akhoondi S, Sun D, von der Lehr N, Apostolidou S, Klotz K, Maljukova A . FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res. 2007; 67(19):9006-12. DOI: 10.1158/0008-5472.CAN-07-1320. View

5.
Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum F, Buchner T . Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2016; 129(4):424-447. PMC: 5291965. DOI: 10.1182/blood-2016-08-733196. View